🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for Chronic Spontaneous Urticaria (CSU)

Mediterranean and Low-Histamine Diets for Pediatric Chronic Spontaneous Urticaria NCT07765979NA1 site📍 Istanbul Saglik Bilimleri Universitesi · Tests: Low-Histamine Diet, Mediterranean Diet Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria NCT05916937Phase 41 site📍 Copenhagen Simon Francis Thomsen · Tests: omalizumab 300 mg every four weeks, omalizumab 300 mg every six weeks Interleukin-2 for Refractory Chronic Spontaneous Urticaria NCT06924762Phase 2, Phase 31 site📍 Changsha Second Xiangya Hospital of Central South University · Tests: Placebo intramuscular injection, Human interleukin-2 (I) intramuscular injection A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. NCT07219615Phase 277 sites📍 Phoenix📍 Little Rock📍 Bakersfield Pfizer · Tests: Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines NCT07415551Phase 230 sites📍 Sofia📍 Sofia📍 Sofia Yuhan Corporation · Tests: Lesigercept, Placebo Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks NCT07816328Phase 35 sites📍 Hong Kong📍 Yokohama📍 Yokohama Novartis Pharmaceuticals · Tests: Remibrutinib, Omalizumab SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria NCT07378527Phase 2, Phase 330 sites📍 Bengbu📍 Wuhu📍 Beijing Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-332 Tablets, ICP-332 placebo Tablets, ICP-332 Tablets Remibrutinib in Real-world Clinical Practice NCT07358364n/a1 site📍 Kirksville Novartis Pharmaceuticals Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. NCT07402213Phase 31 site📍 Beijing Jemincare · Tests: JYB1904, Placebo+JYB1904 Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT) NCT07642557n/a1 site📍 Düren Novartis Pharmaceuticals A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants NCT07005713Phase 19 sites📍 Beijing📍 Chongqing📍 Guangzhou BeOne Medicines · Tests: Tacabrutideg, Placebo Analysis of the Role of IgE Proteoforms in Health and Disease NCT07328178n/a1 site📍 Leuven KU Leuven · Tests: Blood sample collection Trial of JYB1904 in Chronic Spontaneous Urticaria. NCT06509334Phase 21 site📍 Beijing Jemincare · Tests: JYB1904, JYB1904, Omalizumab Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) NCT07166211Phase 21 site📍 Tianjin Keymed Biosciences Co.Ltd · Tests: CM512 injection, placebo A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults NCT07540910Phase 11 site📍 San Antonio Enanta Pharmaceuticals, Inc · Tests: EDP-978, Placebo Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study. NCT07833696n/a1 site📍 Besançon Centre Hospitalier Universitaire de Besancon · Tests: drug effect A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) NCT07717905Phase 1, Phase 210 sites📍 Wuhu📍 Beijing📍 Guangzhou Bambusa Therapeutics · Tests: BBT001, Placebo A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients NCT07408219n/a1 site📍 East Hanover Novartis Pharmaceuticals An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria NCT06927999Phase 23 sites📍 Glenview📍 Cincinnati📍 Berlin ARS Pharmaceuticals, Inc. · Tests: Placebo, 0.5 mg epinephrine, 1 mg epinephrine Remibrutinib in Real-world Clinical Practice - a US Sub-study NCT07358780n/a1 site📍 Kirksville Novartis Pharmaceuticals ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar NCT07425639n/a1 site📍 Montpellier Celltrion HealthCare France · Tests: Omalizumab Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria NCT06865651Phase 217 sites📍 North Miami Beach📍 Glenview📍 Grenoble Novartis Pharmaceuticals · Tests: Remibrutinib, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy